WO2004045652A2 - Biocompatible magnetic materials for the treatment of cancer by means of hyperthermia, and processes for their production - Google Patents
Biocompatible magnetic materials for the treatment of cancer by means of hyperthermia, and processes for their production Download PDFInfo
- Publication number
- WO2004045652A2 WO2004045652A2 PCT/IB2003/006421 IB0306421W WO2004045652A2 WO 2004045652 A2 WO2004045652 A2 WO 2004045652A2 IB 0306421 W IB0306421 W IB 0306421W WO 2004045652 A2 WO2004045652 A2 WO 2004045652A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- biocompatible
- magnetic
- magnetic material
- process according
- crystalline phase
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 31
- 239000000696 magnetic material Substances 0.000 title claims abstract description 28
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 8
- 230000008569 process Effects 0.000 title claims description 18
- 206010028980 Neoplasm Diseases 0.000 title claims description 8
- 206010020843 Hyperthermia Diseases 0.000 title abstract description 8
- 230000036031 hyperthermia Effects 0.000 title abstract description 8
- 201000011510 cancer Diseases 0.000 title description 7
- 238000011282 treatment Methods 0.000 title description 7
- 230000005291 magnetic effect Effects 0.000 claims abstract description 35
- 239000011159 matrix material Substances 0.000 claims abstract description 18
- 238000002844 melting Methods 0.000 claims abstract description 15
- 230000008018 melting Effects 0.000 claims abstract description 15
- 238000000975 co-precipitation Methods 0.000 claims abstract description 9
- 238000005245 sintering Methods 0.000 claims abstract description 8
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 claims description 13
- 238000007669 thermal treatment Methods 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 10
- 229910052681 coesite Inorganic materials 0.000 claims description 8
- 229910052906 cristobalite Inorganic materials 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 229910052682 stishovite Inorganic materials 0.000 claims description 8
- 229910052905 tridymite Inorganic materials 0.000 claims description 8
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- 239000005313 bioactive glass Substances 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 229910000859 α-Fe Inorganic materials 0.000 claims description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 3
- 239000000908 ammonium hydroxide Substances 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- -1 CaHP04-2H20 Inorganic materials 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Inorganic materials [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 claims description 2
- 239000003637 basic solution Substances 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 23
- 238000011275 oncology therapy Methods 0.000 abstract description 2
- 239000002196 Pyroceram Substances 0.000 description 12
- 238000010438 heat treatment Methods 0.000 description 11
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 10
- 230000005294 ferromagnetic effect Effects 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 230000000975 bioactive effect Effects 0.000 description 6
- 238000002513 implantation Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000006911 nucleation Effects 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 229910020630 Co Ni Inorganic materials 0.000 description 2
- 229910002440 Co–Ni Inorganic materials 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229910045601 alloy Inorganic materials 0.000 description 2
- 239000000956 alloy Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Inorganic materials [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229910000388 diammonium phosphate Inorganic materials 0.000 description 1
- 230000005293 ferrimagnetic effect Effects 0.000 description 1
- 239000003302 ferromagnetic material Substances 0.000 description 1
- 238000009217 hyperthermia therapy Methods 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 229910001853 inorganic hydroxide Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000006060 molten glass Substances 0.000 description 1
- 239000012768 molten material Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/06—Magnetotherapy using magnetic fields produced by permanent magnets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03B—MANUFACTURE, SHAPING, OR SUPPLEMENTARY PROCESSES
- C03B19/00—Other methods of shaping glass
- C03B19/06—Other methods of shaping glass by sintering, e.g. by cold isostatic pressing of powders and subsequent sintering, by hot pressing of powders, by sintering slurries or dispersions not undergoing a liquid phase reaction
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C14/00—Glass compositions containing a non-glass component, e.g. compositions containing fibres, filaments, whiskers, platelets, or the like, dispersed in a glass matrix
- C03C14/004—Glass compositions containing a non-glass component, e.g. compositions containing fibres, filaments, whiskers, platelets, or the like, dispersed in a glass matrix the non-glass component being in the form of particles or flakes
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C14/00—Glass compositions containing a non-glass component, e.g. compositions containing fibres, filaments, whiskers, platelets, or the like, dispersed in a glass matrix
- C03C14/006—Glass compositions containing a non-glass component, e.g. compositions containing fibres, filaments, whiskers, platelets, or the like, dispersed in a glass matrix the non-glass component being in the form of microcrystallites, e.g. of optically or electrically active material
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C3/00—Glass compositions
- C03C3/04—Glass compositions containing silica
- C03C3/076—Glass compositions containing silica with 40% to 90% silica, by weight
- C03C3/097—Glass compositions containing silica with 40% to 90% silica, by weight containing phosphorus, niobium or tantalum
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/01—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxide ceramics
- C04B35/16—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxide ceramics based on silicates other than clay
- C04B35/18—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxide ceramics based on silicates other than clay rich in aluminium oxide
- C04B35/19—Alkali metal aluminosilicates, e.g. spodumene
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/01—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxide ceramics
- C04B35/16—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxide ceramics based on silicates other than clay
- C04B35/18—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxide ceramics based on silicates other than clay rich in aluminium oxide
- C04B35/195—Alkaline earth aluminosilicates, e.g. cordierite or anorthite
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/653—Processes involving a melting step
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
- H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
- H01F1/01—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of inorganic materials
- H01F1/03—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of inorganic materials characterised by their coercivity
- H01F1/12—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of inorganic materials characterised by their coercivity of soft-magnetic materials
- H01F1/34—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of inorganic materials characterised by their coercivity of soft-magnetic materials non-metallic substances, e.g. ferrites
- H01F1/36—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of inorganic materials characterised by their coercivity of soft-magnetic materials non-metallic substances, e.g. ferrites in the form of particles
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B2235/00—Aspects relating to ceramic starting mixtures or sintered ceramic products
- C04B2235/02—Composition of constituents of the starting material or of secondary phases of the final product
- C04B2235/30—Constituents and secondary phases not being of a fibrous nature
- C04B2235/32—Metal oxides, mixed metal oxides, or oxide-forming salts thereof, e.g. carbonates, nitrates, (oxy)hydroxides, chlorides
- C04B2235/3201—Alkali metal oxides or oxide-forming salts thereof
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B2235/00—Aspects relating to ceramic starting mixtures or sintered ceramic products
- C04B2235/02—Composition of constituents of the starting material or of secondary phases of the final product
- C04B2235/30—Constituents and secondary phases not being of a fibrous nature
- C04B2235/32—Metal oxides, mixed metal oxides, or oxide-forming salts thereof, e.g. carbonates, nitrates, (oxy)hydroxides, chlorides
- C04B2235/3205—Alkaline earth oxides or oxide forming salts thereof, e.g. beryllium oxide
- C04B2235/3208—Calcium oxide or oxide-forming salts thereof, e.g. lime
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B2235/00—Aspects relating to ceramic starting mixtures or sintered ceramic products
- C04B2235/02—Composition of constituents of the starting material or of secondary phases of the final product
- C04B2235/30—Constituents and secondary phases not being of a fibrous nature
- C04B2235/32—Metal oxides, mixed metal oxides, or oxide-forming salts thereof, e.g. carbonates, nitrates, (oxy)hydroxides, chlorides
- C04B2235/327—Iron group oxides, their mixed metal oxides, or oxide-forming salts thereof
- C04B2235/3272—Iron oxides or oxide forming salts thereof, e.g. hematite, magnetite
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B2235/00—Aspects relating to ceramic starting mixtures or sintered ceramic products
- C04B2235/02—Composition of constituents of the starting material or of secondary phases of the final product
- C04B2235/30—Constituents and secondary phases not being of a fibrous nature
- C04B2235/44—Metal salt constituents or additives chosen for the nature of the anions, e.g. hydrides or acetylacetonate
- C04B2235/447—Phosphates or phosphites, e.g. orthophosphate or hypophosphite
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B2235/00—Aspects relating to ceramic starting mixtures or sintered ceramic products
- C04B2235/02—Composition of constituents of the starting material or of secondary phases of the final product
- C04B2235/50—Constituents or additives of the starting mixture chosen for their shape or used because of their shape or their physical appearance
- C04B2235/54—Particle size related information
- C04B2235/5418—Particle size related information expressed by the size of the particles or aggregates thereof
- C04B2235/5436—Particle size related information expressed by the size of the particles or aggregates thereof micrometer sized, i.e. from 1 to 100 micron
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B2235/00—Aspects relating to ceramic starting mixtures or sintered ceramic products
- C04B2235/70—Aspects relating to sintered or melt-casted ceramic products
- C04B2235/80—Phases present in the sintered or melt-cast ceramic products other than the main phase
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B2235/00—Aspects relating to ceramic starting mixtures or sintered ceramic products
- C04B2235/70—Aspects relating to sintered or melt-casted ceramic products
- C04B2235/96—Properties of ceramic products, e.g. mechanical properties such as strength, toughness, wear resistance
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B2235/00—Aspects relating to ceramic starting mixtures or sintered ceramic products
- C04B2235/70—Aspects relating to sintered or melt-casted ceramic products
- C04B2235/96—Properties of ceramic products, e.g. mechanical properties such as strength, toughness, wear resistance
- C04B2235/9607—Thermal properties, e.g. thermal expansion coefficient
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
- H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
- H01F1/01—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of inorganic materials
- H01F1/03—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of inorganic materials characterised by their coercivity
- H01F1/12—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of inorganic materials characterised by their coercivity of soft-magnetic materials
- H01F1/34—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of inorganic materials characterised by their coercivity of soft-magnetic materials non-metallic substances, e.g. ferrites
- H01F1/342—Oxides
- H01F1/344—Ferrites, e.g. having a cubic spinel structure (X2+O)(Y23+O3), e.g. magnetite Fe3O4
Definitions
- Yet another purpose of the present invention consists in providing a biocompatible magnetic material suitable for the treatment of cancer by means of hyperthermia that is obtainable by three modes of production.
- biocompatible magnetic material of the invention is obtainable by alternative methods of production, which comprise coprecipitation, melting, and sintering of the starting compounds.
- the aqueous solutions of the reagent salts are mixed, after which the- base is added so as to obtain a precipitate, which is washed with distilled water, filtered, and preferably dried in a stove at a temperature of 150- 200°C.
- the dry powder obtained is preferably ground and treated thermally at a temperature at which it decomposes, typically in the range between 600°C and 900°C.
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Ceramic Engineering (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Materials Engineering (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Manufacturing & Machinery (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Dispersion Chemistry (AREA)
- Structural Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Geochemistry & Mineralogy (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Power Engineering (AREA)
- Crystallography & Structural Chemistry (AREA)
- Magnetic Treatment Devices (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to the production of biocompatible magnetic materials for cancer therapy by means of hyperthermia. These materials are constituted by a biocompatible vitreous matrix in which there is dispersed a magnetic crystalline phase. The magnetic materials of the invention may be obtained with three different methodologies: coprecipitation, melting, and sintering.
Description
Biocompatible magnetic materials for the treatment of cancer by means of hyperthermia, and processes for their production
DESCRIPTION
The present invention relates to the 'development of biocompatible magnetic materials suitable for the treatment of tumoural forms by means of hyperthermia, as well as to the corresponding methods of preparation.
Notoriously, cancer cells are particularly sensitive to heat. It has in fact been verified that when they are heated to a temperature higher than 42.5°C their structure is seriously damaged or destroyed.
This phenomenon is exploited in modern therapeutic techniques to obtain a localized hypothermia on diseased organs of the human body and to bring about selective destruction of cancer cells and neoplastic tissues.
Notoriously, the heating of biological tissues can be obtained using different modalities of generation and transmission of heat.
In techniques of hyperthermia therapy, recourse is had to three types of localized heating: the first
envisages indirect heating of the tissues by setting them in contact with a liquid brought up to an appropriate temperature, the second envisages direct heating of the tissues as a result of electrical currents, whilst the third type exploits indirect heating of the tissues using implantable magnetic elements and applying a variable magnetic field.
The therapeutic methodologies that have gained most ground in the medical sector envisage the implantation or localized application of ferromagnetic materials or devices in the form of rods, needles, granules, or powders, and their heating by means of magnetic fields. It is in fact found that, with the introduction of small magnetic bodies at the level of the tissues affected by neoplastic forms, it is possible to obtain a localized heating of the diseased tissues by application of appropriate magnetic fields. Generally, for these therapeutic applications metals, (Fe-Co-Ni-based) metal alloys, metal oxides, such as Fe203 and Fe30, and ferrites are used.
There is likewise known a therapeutic technique that envisages the implantation of filaments of ferromagnetic alloys and their exposure to an external oscillating magnetic field of pre-set frequency and intensity so as to induce heating thereof.
The ferromagnetic alloys used in these applications are Fe-Co-Ni-based, Ni-Pd-based, and Fe- Pd-based ones .
It is, however, found that these metal materials, once implanted directly in the tissues of the human body, have an undesirable high thermal conductivity that damages the healthy tissues surrounding the implantation area. Furthermore, the reactivity of these magnetic materials leads to the release in biological fluids of metal ions that are toxic for the organism.
In order to attempt to overcome the above drawbacks, materials susceptible to magnetic fields have been developed, in which the ferromagnetic phases have been incorporated in inert matrices, such as glasses and pyroceram.
However, it is found that the aforesaid inert matrices do not have an adequate affinity and biocompatibility with the tissues of the human organism and are thus perceived as foreign bodies.
In addition, it is found that the use of inert matrices with reduced biocompatibility frequently determines the onset of phenomena of local sensitization and the possible development of serious side effects that can occur also immediately after
their implantation in the organism.
There are moreover known materials that contain a magnetic phase inserted in components compatible with the human organism, such as proteins, certain polymers, and biocompatible pyrocera materials. The latter contain, in addition to the ferromagnetic phase', other non-magnetic crystalline phases.
It is, however, found that these materials of more recent production require the use of very intense variable magnetic fields, which are difficult to obtain within hospital structures.
At the current state of the art, there is hence felt the need to have available new biologically compatible magnetic materials , that will be readily usable within hospital structures.
One of the general purposes of the present invention consists then in providing a magnetic material for cancer therapy by means of hyperthermia that has a high biocompatibility with the tissues of the human organism and an adequate susceptibility to magnetic fields.
A further purpose of the invention consists in providing methods for making magnetic materials, suitable for thermal treatment of tumoural forms, which are also readily obtainable and do not entail
high production costs.
Yet another purpose of the present invention consists in providing a biocompatible magnetic material suitable for the treatment of cancer by means of hyperthermia that is obtainable by three modes of production.
In the light of these purposes and of still others, which will emerge more evidently hereinafter, there is provided, according to a first aspect of the present invention, a biocompatible magnetic material for the treatment of cancer by means of hyperthermia consisting of a magnetic crystalline phase and a biocompatible matrix in which said biocompatible matrix is a bioactive glass.
Conveniently, in the material of the invention the magnetic crystalline phase is incorporated in the biologically compatible vitreous matrix so that, when the material is implanted and subjected to the action of magnetic fields toxic ions are not released into the organism.
The ferromagnetic phase used in the context of the invention comprises all the materials that undergo heating when they are subjected to the action of a magnetic field, such as, for example, ferromagnetic, ferrimagnetic and/or superparamagnetic materials.
Magnetic materials that are particularly suitable for the purpose according to the present invention are chosen from among ferrites. A typical example of a particularly suitable ferrite is magnetite (FeO'Fe:03) .
The crystalline ferromagnetic phase, responsible for heating of the material of the invention when subjected to the influence of a magnetic field, is to advantage present in an amount of not less than 30 wt% with respect to the overall weight of the material of the invention.
The ferromagnetic phase incorporated within a biologically compatible vitreous matrix, when inserted in the human body, is not perceived as a foreign body and does not substantially have any side effects.
As biologically compatible vitreous matrix bioactive glasses are used. The term "glass" defines a material obtained through thermal treatment at high temperature of mixtures of oxides up to melting. The molten material, during its subsequent cooling, passes to the solid state without crystallizing, maintaining an amorphous (i.e., disorderly, non-crystalline) structure typical of a liquid. Through subsequent thermal treatments of nucleation and growth, or else by observing appropriate conditions of cooling of the liquid, it is possible to obtain a pyroceram material,
i.e., one in which the formation of crystals of appropriate composition and dimensions, incorporated in the residual amorphous matrix, is induced.
By "biocompatibility" is meant the capacity of a material to stimulate, once implanted, a specific response on the part of the organism that hosts it, without triggering any adverse reactions. In the case of a bioactive glass this response consists in favouring the growth of healthy tissue on its surface.
The biocompatible magnetic material that forms the subject of the present invention may be obtained in different forms: massive objects, granules and/or powders with dimensions comprised between a few micron up to a few centimetres, according to the applications envisaged.
The biocompatible magnetic material that forms the subject of this invention can be applied in a living organism by means of implantation techniques or by means of local application. The high affinity of the vitreous matrix with the tissues of the human organism prevents the onset of side effects and allergic reactions.
The biocompatible magnetic material of the invention is suitable in localized treatment by means of hyperthermia and in particular in the selective
treatment of tumoural forms, including ones located in internal organs or tissues of the human body.
The biocompatible magnetic material of the invention is obtainable by alternative methods of production, which comprise coprecipitation, melting, and sintering of the starting compounds.
According to one of the embodiments, there is described a method for obtaining the biocompatible magnetic materials of the invention that comprises the coprecipitation of the precursor reagents of the oxides that form pyroceram. The reagents in question are water-soluble salts. Preferably, soluble salts of inorganic acids are used, such as, for example, sulphates, chlorides, nitrates, carbonates, and phosphates that precipitate in a basic medium. According to this embodiment, the components are mixed at a colloidal or molecular level.
Coprecipitation occurs in a basic medium, i.e., a solution of a base suitable for converting the metal salt into an oxide. Appropriate bases are preferably inorganic hydroxides, such as sodium hydroxide, lithium hydroxide, ammonium hydroxide, and mixtures thereof. The salts are solubilized in cold or hot water.
Conveniently, in the initial step the aqueous
solutions of the reagent salts are mixed, after which the- base is added so as to obtain a precipitate, which is washed with distilled water, filtered, and preferably dried in a stove at a temperature of 150- 200°C. The dry powder obtained is preferably ground and treated thermally at a temperature at which it decomposes, typically in the range between 600°C and 900°C.
In the final step, the decomposed powder is subjected to thermal treatment at the melting point of the material obtained.
Typically, a temperature higher than to 1400°C is used, conveniently in the range between 1400°C and l'βOO°C, so that the pyroceram material obtained will contain basically only the magnetic phase. The magnetic phase is formed during cooling.
According , to another embodiment, the biocompatible magnetic material of the invention is obtained by means of melting of the reagents constituted by a mixture of insoluble powders of metal salts or oxides. The temperature required for melting of the reagents is' higher than the temperature required in the process of coprecipitation since the precursors, being in a solid form, have a lower chemical homogeneity. Generally the melting
P T/IB2003/006421
temperatures required are higher than 1500°C, and typically are in the range between 1550°C and 1600°C.
According to another embodiment, the biocompatible magnetic material of the invention is obtained by means of sintering of the matrix in bioactive glass with the magnetic crystalline phase.
The bioactive vitreous matrix and the magnetic crystalline phase can be prepared separately. The vitreous matrix can be obtained with the methods for obtaining glasses, or alternatively a commercially available glass is used. The magnetic crystalline phase may be obtained by conventional chemical reactions, or alternatively a commercially available product is used.
Conveniently, the bioactive vitreous phase and the magnetic crystalline phase are first mixed, pressed, and then treated thermally at a sintering temperature, preferably in the range between 900°C and 1000°C. Finally, a sintered composite material is obtained, which incorporates the magnetic phase in the bioactive vitreous matrix.
The following examples are provided purely by way of illustration of the present invention and are not to be understood as in any sense limiting the sphere of protection thereof, as defined in the annexed
claims . Example 1
This example illustrates the preparation of a pyroceram material containing magnetite, according to the invention, by means of a process of coprecipitation .
The oxide composition used for making the pyroceram was the following: 13.5 wt% Na20, 13.5 wt% CaO, 24.5 wt% Si02, 3.3 wt% P205, 14 wt% FeO, 31 wt% Fe203. The amount of FeO and Fe203 was calculated to form 45 wt% of magnetite, in accordance with the chemical reaction (molar ratio between FeO and Fe203 = 1) :
FeO + Fe203 => FeO-Fe203 = Fe30
The reagents used were water-soluble salts: NaN03,
Ca(N03)2'4H20, colloidal Si02, (NH4)2HP04, FeS04-7H20,
Fe(NH4) (S04)2'12H20.
The stoichiometric amounts for forming the oxides of these salts were solubilized separately in water (with the exception of the colloidal Si02, which is already an aqueous solution) using a magnetic stirrer on a hot plate.
The various aqueous solutions were then mixed under magnetic stirring. Finally, ammonium hydroxide was ll
B2003/006421
added, until an abundant precipitate was formed. The precipitate was washed repeatedly with distilled water, filtered, and dried in a stove at a temperature of 200°C. The dried powder was ground, after which it underwent thermal treatment at 900°C for 3 hours.
During thermal treatment, the mixed salts were decomposed with the development of NOv-based, SOx- based, C02-based, and NH3-based vapours. The powder obtained after the thermal treatment was melted in a platinum crucible at 1500°C for 30 minutes, and the product was poured onto a copper plate at room temperature .
In this way a pyroceram was obtained which contained only the magnetite crystals in a biocompatible and bioactive vitreous matrix; there was hence no need for any subsequent thermal treatment of nucleation and growth.
Example 2
This example illustrates the preparation of a pyroceram material containing magnetite, according to the invention, by means of a process of melting.
The oxide composition of the pyroceram used was the one given in Example 1.
The reagents used were Na2C03, CaC03, Si02, CaHP04-2H20,
Fe203, FeS04'7H20.
These reagents were mixed in stoichiometric amounts corresponding to the oxide composition and were melted in a platinum crucible at 1550°C. After 30 minutes of maintenance at the melting temperature, the liquid (molten glass) was poured onto a copper plate at room temperature. There was thus obtained a pyroceram that contained only the magnetite crystals in a biocompatible and bioactive vitreous matrix. • The method of the invention renders superfluous any subsequent thermal treatment of nucleation and growth. Example 3
This example illustrates the preparation of a pyroceram material containing magnetite, according to the invention, by means of the sintering process. The sintered material contained a vitreous matrix and the dispersed magnetite phase (45 wt%) . The oxide composition of the commercial glass used was the following: 24.5 wt% Na20, 24.5 wt% CaO, 45 wt% Si02, 6 wt% P205.
The bioactive and biocompatible glass was obtained using the melting method.
The reagents Na2C03, CaC03, Si02, and Ca3(P04)2 were mixed and melted at a temperature of 1500°C for 30 minutes. The liquid was poured at room temperature onto a copper plate to obtain a glass. The glass thus
6421
obtained was ground and sieved to obtain powders with different grain size: one part below 38 μm and a second part between 38 μm and 106 μm. There were mixed together the fraction with a grain size between 38 μm and 106 μm in a proportion of 45 wt%, the fraction with a grain size below 38 μm in a proportion of 10 wtS, and the magnetite with a grain size of 5 μm (Aldrich) in a proportion of 45 wt%.
After mixing, the powders were pressed into the form of disks (30 mm in diameter) using a uniaxial cold press and applying a force of 8 tonnes for 5 seconds. The disks were sintered at a temperature of 900°C for 1 hour in an inert atmosphere (argon) . The resulting material was a pyroceram containing magnetite crystals englobed in a vitreous phase. Example 4
Hysteresis cycles were performed for the materials obtained in the foregoing examples (1-3) using a vibration magnetometer. The magnetic field used was 15 koersted.
The attached Figure 1 is a graphic representation of the results obtained. The magnetic characteristics of the pyrocera s illustrated in Figure 1 are given in Table 1:
Table 1
Illustrated in the attached Figure 2 is a graph that gives on the abscissa the time and on the ordinate the temperature values for a specimen prepared as described in Example 1 by a process of coprecipitation and after application of a very strong variable magnetic field (450 kHz, 1 k ) . The power supplied was 40-50 W/g.
By adjusting the frequency and the intensity • of the magnetic field applied it is possible to adjust the temperature of heating of the material of the invention so as to reach the optimal temperature for destruction of cancer tissues, which may conveniently be set approximately in the 41-46°C range or higher according to the applications. Example 5 Given in this example are the general properties of
magnetite .
Claims
1. A biocompatible magnetic material for the thermal treatment of neoplasms comprising a magnetic crystalline phase and a biocompatible matrix in which said biocompatible matrix is a bioactive glass.
2. The biocompatible magnetic material according to Claim 1, in which said magnetic crystalline phase is dispersed in said biocompatible matrix.
3. The biocompatible magnetic material according to Claim 1 or Claim 2, in which said magnetic crystalline phase is a magnetic material chosen from among ferrites .
4. The biocompatible magnetic material according to any one of Claims 1-3, in which said magnetic crystalline phase is magnetite.
5. The biocompatible magnetic material according to any one of Claims 1-4, in which said magnetic crystalline phase is present in an amount of not less than 30 wt% .
6. A process for producing a biocompatible magnetic material according to Claim 1, comprising melting of a mixture of Na2C03, CaC03, Si02, CaHP04-2H20, Fe203, and FeS04-7H20, and subsequent cooling thereof.
7. The process according to Claim 6, in which melting of the reagents occurs at a temperature of between 1500°C and 1600°C.
8. The process according to Claim 7, in which said reagents are kept at the melting temperature for a period of at least 30 minutes.
9. The process for making a biocompatible magnetic material according to Claim 1, comprising the mixing of, a vitreous phase and a magnetic crystalline phase, and the sintering of the mixture in an inert or reducing atmosphere.
10. The process according to Claim 9, in which the step of sintering occurs at a temperature of between 900°C and 1000°C.
11. The process according to Claim 9 or 10, in which said crystalline and vitreous phases are pressed prior to being subjected to sintering.
12. The process for the production of a biocompatible magnetic material according to Claim 1, comprising the coprecipitation of water-soluble salts of Na, Ca, P, Fe and of colloidal Si02 in a basic solution and the thermal treatment of the powder thus obtained.
13. The process according to Claim 12, in which the water-soluble salts are NaN03, Ca (N03) 2 ' 4H20, (NH)2HP0, FeS0-7H20, and Fe(NH4) (S04) 2-12H20.
14. The process according to Claim 12 or Claim 13, in which said basic solution is an aqueous solution chosen from among sodium hydroxide, lithium hydroxide, ammonium hydroxide, and mixtures thereof.
15. The process according to any one of Claims 12 to 14, in which subsequently the dry precipitate obtained from the coprecipitation step is ground and subjected to a thermal treatment to decompose the components of the precipitate and then to subsequent melting.
16. The process according to any one of Claims 12 to 15, in which the melting temperature is in the range between 1400°C and 1600°C.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITTO20020994 ITTO20020994A1 (en) | 2002-11-15 | 2002-11-15 | BIOCOMPATIBLE MAGNETIC MATERIALS FOR THE TREATMENT OF CANCER THROUGH HYPERTHERMIA, AND PROCESSES FOR THEIR REALIZATION. |
| ITTO2002A000994 | 2002-11-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2004045652A2 true WO2004045652A2 (en) | 2004-06-03 |
| WO2004045652A3 WO2004045652A3 (en) | 2004-10-21 |
Family
ID=32321455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2003/006421 WO2004045652A2 (en) | 2002-11-15 | 2003-11-14 | Biocompatible magnetic materials for the treatment of cancer by means of hyperthermia, and processes for their production |
Country Status (2)
| Country | Link |
|---|---|
| IT (1) | ITTO20020994A1 (en) |
| WO (1) | WO2004045652A2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009100716A2 (en) * | 2008-02-11 | 2009-08-20 | Magforce Nanotechnologies Ag | Implantable products comprising nanoparticles |
| CN103979797A (en) * | 2014-05-23 | 2014-08-13 | 南通市中友钢化玻璃制造有限公司 | Production technology of permanent-magnetic glass |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4323056A (en) * | 1980-05-19 | 1982-04-06 | Corning Glass Works | Radio frequency induced hyperthermia for tumor therapy |
| EP0361797A1 (en) * | 1988-09-26 | 1990-04-04 | Kyoto University | Heat-generating ceramics body for hyperthermia and method of producing the same |
-
2002
- 2002-11-15 IT ITTO20020994 patent/ITTO20020994A1/en unknown
-
2003
- 2003-11-14 WO PCT/IB2003/006421 patent/WO2004045652A2/en not_active Application Discontinuation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4323056A (en) * | 1980-05-19 | 1982-04-06 | Corning Glass Works | Radio frequency induced hyperthermia for tumor therapy |
| EP0361797A1 (en) * | 1988-09-26 | 1990-04-04 | Kyoto University | Heat-generating ceramics body for hyperthermia and method of producing the same |
Non-Patent Citations (3)
| Title |
|---|
| EBISAWA Y ET AL: "Bioactivity of ferrimagnetic glass-ceramics in the system FeO-Fe2O3-CaO-SiO2" BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 18, no. 19, 1997, pages 1277-1284, XP004088021 ISSN: 0142-9612 * |
| OH, SEUNG-HAN ET AL: "Research on annihilation of cancer cells by glass-ceramics for cancer treatment with external magnetic field. I. Preparation and cytotoxicity" JOURNAL OF BIOMEDICAL MATERIALS RESEARCH , VOLUME DATE 2001, 54(3), 360-365 CODEN: JBMRBG; ISSN: 0021-9304, 2000, XP002290947 * |
| TADASHI KOKUBO: "BIOACTIVE GLASS CERAMICS: PROPERTIES AND APPLICATIONS" BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 12, no. 2, 1 March 1991 (1991-03-01), pages 155-163, XP000179579 ISSN: 0142-9612 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009100716A2 (en) * | 2008-02-11 | 2009-08-20 | Magforce Nanotechnologies Ag | Implantable products comprising nanoparticles |
| WO2009100716A3 (en) * | 2008-02-11 | 2010-09-23 | Magforce Nanotechnologies Ag | Implantable products comprising nanoparticles |
| AU2009214533B2 (en) * | 2008-02-11 | 2015-01-29 | Magforce Ag | Implantable products comprising nanoparticles |
| CN103979797A (en) * | 2014-05-23 | 2014-08-13 | 南通市中友钢化玻璃制造有限公司 | Production technology of permanent-magnetic glass |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004045652A3 (en) | 2004-10-21 |
| ITTO20020994A1 (en) | 2004-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR0157033B1 (en) | Heat-generating ceramics body for hyperthermia and method of producing the same | |
| US4574782A (en) | Radio frequency-induced hyperthermia for tumor therapy | |
| CA2177034C (en) | Cobalt palladium seeds for thermal treatment of tumors | |
| Bretcanu et al. | Synthesis and characterization of coprecipitation-derived ferrimagnetic glass-ceramic | |
| Arcos et al. | A novel bioactive and magnetic biphasic material | |
| Murakami et al. | Hydrothermal synthesis of magnetite/hydroxyapatite composite material for hyperthermia therapy for bone cancer | |
| Shah et al. | Magnetic and bioactivity evaluation of ferrimagnetic ZnFe2O4 containing glass ceramics for the hyperthermia treatment of cancer | |
| Lee et al. | Crystallization and properties of Fe2O3—CaO—SiO2 glasses | |
| US5468210A (en) | Process of thermal treatment in tissue | |
| EP0040512A1 (en) | Ceramic suitable for inducing localised heating in the presence of a radio frequency magnetic field, and use thereof | |
| Abdel-Hameed et al. | Effect of P2O5 and MnO2 on crystallization of magnetic glass ceramics | |
| Martinelli et al. | Synthesis and characterization of glass–ceramic microspheres for thermotherapy | |
| Ruiz‐Hernández et al. | Glass–glass ceramic thermoseeds for hyperthermic treatment of bone tumors | |
| Abdel-Hameed et al. | Preparation and characterization of some ferromagnetic glass–ceramics contains high quantity of magnetite | |
| Abdel-Hameed et al. | Magnetic glass ceramics for sustained 5-fluorouracil delivery: Characterization and evaluation of drug release kinetics | |
| WO2004045652A2 (en) | Biocompatible magnetic materials for the treatment of cancer by means of hyperthermia, and processes for their production | |
| JPH0718357A (en) | Combined functional material device | |
| Ramanujan et al. | Magnetic particles for hyperthermia treatment of cancer | |
| JP2829997B2 (en) | Preparation of ceramic heating elements for hyperthermia | |
| JP2007325850A (en) | Microcapsule heating element for thermotherapy and its manufacturing method | |
| KR0157034B1 (en) | Method of producing heat generating ceramics body for hyperthermia | |
| KR101319220B1 (en) | Method for preparing magnetic hydroxyapatite nanotubes | |
| Beherei et al. | Bio-physiochemical characterization of anticancer nano-ceramic polymer scaffold for bone grafting | |
| El-Kheshen et al. | Effect of composition on bioactivity and magnetic properties of glass/ceramic composites for hyperthermia | |
| CN1141154C (en) | Heating body capable of controlling its temperature and its making process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase in: |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |